MiNK Therapeutics, Inc. (INKT)
Automate Your Wheel Strategy on INKT
With Tiblio's Option Bot, you can configure your own wheel strategy including INKT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INKT
- Rev/Share 0.0
- Book/Share 107.625
- PB 0.0
- Debt/Equity 0.0
- CurrentRatio 0.2954
- ROIC 0.0009
- MktCap 28935870.0
- FreeCF/Share -33.9948
- PFCF -0.0215
- PE -0.1038
- Debt/Assets 0.0
- DivYield 0
- ROE 206.5428
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
Published: June 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 18, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.
Read More
MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
Published: June 02, 2025 by: GlobeNewsWire
Sentiment: Neutral
Non-dilutive NIH funding supports development of MiNK's allogeneic iNKT platform for immune regulation in high-risk HSCT settings Non-dilutive NIH funding supports development of MiNK's allogeneic iNKT platform for immune regulation in high-risk HSCT settings
Read More
MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q1 2025 Earnings Conference Call May 15, 2025 8:30 AM ET Company Participants Zack Armen - IR Jennifer Buell - President and CEO Christine Klaskin - Principal Financial and Accounting Officer Thiago Favano - Senior Director, Portfolio Operations Conference Call Participants Emily Bodnar - H.C. Wainwright Matt Phipps - William Blair Operator Thank you for standing by.
Read More
MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
Published: May 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Read More
MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript
Published: March 18, 2025 by: Seeking Alpha
Sentiment: Neutral
MiNK Therapeutics, Inc. (NASDAQ:INKT ) Q4 2024 Earnings Conference Call March 18, 2025 8:30 AM ET Company Participants Zack Armen - Investor Relations Dr. Jennifer Buell - President and CEO Christine Klaskin - Principal Financial and Accounting Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Mayank Mamtani - B.
Read More
MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has been selected for an oral presentation at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. The oral presentation will highlight interim data from the company's ongoing Phase 2 study testing AgenT-797 in combination with Agenus' lead therapeutic combination, botensilimab and balstilimab …
Read More
About MiNK Therapeutics, Inc. (INKT)
- IPO Date 2021-10-15
- Website https://minktherapeutics.com
- Industry Biotechnology
- CEO Dr. Jennifer S. Buell Ph.D.
- Employees 23